دورية أكاديمية
أعرض في EDS

Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.

التفاصيل البيبلوغرافية
العنوان: Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.
المؤلفون: Eapen M; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Brazauskas R; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI., Williams DA; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA., Walters MC; University of California San Francisco Benioff Children's Hospital, Oakland, CA., St Martin A; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Jacobs BL; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Antin JH; Dana-Farber Cancer Center, Harvard Medical School, Boston, MA., Bona K; Dana-Farber Cancer Center, Harvard Medical School, Boston, MA., Chaudhury S; Ann and Robert H. Lurie Children's Hospital, Chicago, IL., Coleman-Cowger VH; The Emmes Company LLC, Rockville, MD., DiFronzo NL; National Heart Lung and Blood Institute, Bethesda, MD., Esrick EB; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA., Field JJ; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Fitzhugh CD; Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD., Kanter J; University of Alabama Birmingham, Birmingham, AL., Kapoor N; Children's Hospital of Los Angeles, Los Angeles, CA., Kohn DB; David Geffen School of Medicine, University of California, Los Angeles, CA., Krishnamurti L; David Geffen School of Medicine, University of California, Los Angeles, CA., London WB; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA., Pulsipher MA; Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT., Talib S; California Institute for Regenerative Medicine, San Francisco, CA., Thompson AA; Children's Hospital of Philadelphia, Philadelphia, PA., Waller EK; Emory University, Atlanta, GA., Wun T; University of California Davis School of Medicine, Davis, CA., Horowitz MM; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Apr 20; Vol. 41 (12), pp. 2227-2237. Date of Electronic Publication: 2023 Jan 09.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2003- : Alexandria, VA : American Society of Clinical Oncology
Original Publication: New York, N.Y. : Grune & Stratton, c1983-
مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*/adverse effects , Graft vs Host Disease*/etiology , Leukemia, Myeloid, Acute* , Anemia, Sickle Cell*/etiology , Neoplasms, Second Primary*/epidemiology , Neoplasms, Second Primary*/etiology, Humans ; Cyclophosphamide ; Transplantation Conditioning/adverse effects ; Whole-Body Irradiation
مستخلص: Purpose: To report the incidence and risk factors for secondary neoplasm after transplantation for sickle cell disease.
Methods: Included are 1,096 transplants for sickle cell disease between 1991 and 2016. There were 22 secondary neoplasms. Types included leukemia/myelodysplastic syndrome (MDS; n = 15) and solid tumor (n = 7). Fine-Gray regression models examined for risk factors for leukemia/MDS and any secondary neoplasm.
Results: The 10-year incidence of leukemia/MDS was 1.7% (95% CI, 0.90 to 2.9) and of any secondary neoplasm was 2.4% (95% CI, 1.4 to 3.8). After adjusting for other risk factors, risks for leukemia/MDS (hazard ratio, 22.69; 95% CI, 4.34 to 118.66; P = .0002) or any secondary neoplasm (hazard ratio, 7.78; 95% CI, 2.20 to 27.53; P = .0015) were higher with low-intensity (nonmyeloablative) regimens compared with more intense regimens. All low-intensity regimens included total-body irradiation (TBI 300 or 400 cGy with alemtuzumab, TBI 300 or 400 cGy with cyclophosphamide, TBI 200, 300, or 400 cGy with cyclophosphamide and fludarabine, or TBI 200 cGy with fludarabine). None of the patients receiving myeloablative and only 23% of those receiving reduced-intensity regimens received TBI.
Conclusion: Low-intensity regimens rely on tolerance induction and establishment of mixed-donor chimerism. Persistence of host cells exposed to low-dose radiation triggering myeloid malignancy is one plausible etiology. Pre-existing myeloid mutations and prior inflammation may also contribute but could not be studied using our data source. Choosing conditioning regimens likely to result in full-donor chimerism may in part mitigate the higher risk for leukemia/MDS.
التعليقات: Comment in: J Clin Oncol. 2023 Jun 10;41(17):3272-3273. (PMID: 37043702)
References: Leuk Lymphoma. 2018 Jan;59(1):241-244. (PMID: 28587497)
Blood. 2009 Jan 29;113(5):1175-83. (PMID: 18971419)
Stat Med. 1997 Apr 30;16(8):901-10. (PMID: 9160487)
Nat Genet. 2020 Nov;52(11):1219-1226. (PMID: 33106634)
Blood. 2020 Apr 2;135(14):1185-1188. (PMID: 32062672)
Bone Marrow Transplant. 2019 Nov;54(11):1859-1867. (PMID: 31089288)
Blood. 2022 Sep 8;140(10):1067-1074. (PMID: 35468199)
Bone Marrow Transplant. 2013 Oct;48(10):1335-41. (PMID: 23604009)
Blood. 2011 Nov 3;118(18):5031-9. (PMID: 21900190)
Blood. 2011 Jan 6;117(1):316-22. (PMID: 20926773)
Haematologica. 2020 Jan;105(1):91-101. (PMID: 31097628)
Lancet Haematol. 2019 Nov;6(11):e585-e596. (PMID: 31495699)
Blood. 2017 Sep 28;130(13):1597-1599. (PMID: 28830890)
Haematologica. 2019 Dec;104(12):e543-e546. (PMID: 31018975)
Curr Opin Genet Dev. 2021 Feb;66:63-69. (PMID: 33422951)
Blood. 2022 Dec 8;140(23):2514-2518. (PMID: 36044658)
J Clin Oncol. 2003 Apr 1;21(7):1352-8. (PMID: 12663726)
Radiat Res. 2011 Jun;175(6):677-88. (PMID: 21486161)
Bone Marrow Transplant. 2013 Apr;48(4):537-43. (PMID: 23222384)
Blood. 2021 Nov 25;138(21):2148-2152. (PMID: 34521115)
Blood. 2017 Mar 16;129(11):1548-1556. (PMID: 27965196)
J R Soc Med. 2016 Aug;109(8):303-9. (PMID: 27325377)
Mod Pathol. 2019 Dec;32(12):1712-1726. (PMID: 31371806)
BMC Med Genomics. 2015 May 12;8:22. (PMID: 25963628)
J Clin Invest. 2022 Feb 15;132(4):. (PMID: 34990411)
Blood. 2017 Oct 26;130(17):1946-1948. (PMID: 28887325)
Blood Adv. 2020 May 12;4(9):2084-2094. (PMID: 32396620)
Blood. 2021 Sep 16;138(11):942-947. (PMID: 34115136)
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33. (PMID: 19896087)
Biol Blood Marrow Transplant. 2019 Jun;25(6):1197-1209. (PMID: 30500440)
Radiat Res. 2013 Mar;179(3):361-82. (PMID: 23398354)
JAMA. 2014 Jul 2;312(1):48-56. (PMID: 25058217)
N Engl J Med. 2022 Jan 13;386(2):138-147. (PMID: 34898140)
Bone Marrow Transplant. 2017 Jun;52(6):938-940. (PMID: 28436975)
Transplant Cell Ther. 2022 Jun;28(6):325.e1-325.e7. (PMID: 35302009)
Blood. 2016 Nov 24;128(21):2561-2567. (PMID: 27625358)
Blood. 2012 Nov 22;120(22):4285-91. (PMID: 22955919)
Blood Adv. 2020 May 12;4(9):2058-2063. (PMID: 32396618)
Blood. 2019 Jun 27;133(26):2790-2799. (PMID: 30992266)
Lancet Haematol. 2019 Apr;6(4):e183-e193. (PMID: 30878319)
معلومات مُعتمدة: OT3 HL147741 United States HL NHLBI NIH HHS; R01 AI145231 United States AI NIAID NIH HHS; U24 CA076518 United States CA NCI NIH HHS
المشرفين على المادة: 8N3DW7272P (Cyclophosphamide)
تواريخ الأحداث: Date Created: 20230109 Date Completed: 20230419 Latest Revision: 20240421
رمز التحديث: 20240421
مُعرف محوري في PubMed: PMC10448940
DOI: 10.1200/JCO.22.01203
PMID: 36623245
قاعدة البيانات: MEDLINE
الوصف
تدمد:1527-7755
DOI:10.1200/JCO.22.01203